Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with acute coronary syndrome (ST-depression in at least 2 leads \> 0,1 mV), or T-wave inversion, with or without elevated myocardial biomarkers (Troponin T oder I), together with typical clinical presentation), treated as follows:~* Acute percutaneous revascularization with stent implantation within 48 hours after symptom onset.~* Successful acute PCI (residual stenosis \< 30%, TIMI flow \> 2).~* Hemodynamic stability~* Age 18 - 80 years~* Written informed consent~* Active contraception in women of childbearing age~Exclusion Criteria:~* Patients with STEMI (ST elevation in 2 leads above 0,2 mV in lead V1, V2 oder V3 or above 0,1 mV in the other leads)~* Necessity of additional PCI in non-infarct vessel at the time of study therapy (multi-vessel PCI in the acute event is possible)~* Heart failure (LVEF ≤ 30 %).~* Arteriovenous malformation or aneurysms~* Active infection (C-reactive protein \> 10 mg/dl), or fever, or diarrhoea within the last 4 weeks~* Chronic inflammatory disease~* HIV infection or active hepatitis~* Neoplastic disease without documented complete remission within the last 5 years~* Recent stroke within the last 3 months~* Impaired kidney function (creatinin \> 2,5 mg/dl) at the time of treatment~* Significant liver disease (GOT \> 2x upper normal value or spontaneous INR \> 1,5.~* Hematopoetic disease (anaemia with Hb\< 8.5 mg/dl; thrombocytopenia \< 100.000/µl; splenomegaly~* Known allergies to Clopidogrel, Heparin or Abciximab~* History of bleeding disorder~* GI bleeding within the last 3 months~* Major surgery or trauma within the last 2 months~* Uncontrolled hypertension~* Pregnancy~* Mental disability~* Previous progenitor cell therapy~* Participation in a different clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
- 2 (Type: PLACEBO_COMPARATOR): Intracoronary infusion of Placebo after NSTEMI

Based on this trial design, predict the completion outcome and termination type (if applicable).